Cargando…

In vivo retention of (18)F-AV-1451 in corticobasal syndrome

OBJECTIVE: To study the usefulness of (18)F-AV-1451 PET in patients with corticobasal syndrome (CBS). METHODS: We recruited 8 patients with CBS, 17 controls, 31 patients with Alzheimer disease (AD), and 11 patients with progressive supranuclear palsy (PSP) from the Swedish BioFINDER study. All patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Ruben, Schöll, Michael, Widner, Håkan, van Westen, Danielle, Svenningsson, Per, Hägerström, Douglas, Ohlsson, Tomas, Jögi, Jonas, Nilsson, Christer, Hansson, Oskar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580862/ https://www.ncbi.nlm.nih.gov/pubmed/28754841 http://dx.doi.org/10.1212/WNL.0000000000004264

Ejemplares similares

Increased basal ganglia binding of (18) F‐AV‐1451 in patients with progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2018)

(18)F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies
por: Smith, Ruben, et al.
Publicado: (2018)

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

(18)F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers
por: Smith, Ruben, et al.
Publicado: (2016)

Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks
por: Hansson, Oskar, et al.
Publicado: (2017)

Increased retention of tau PET ligand [(18)F]-AV1451 in Alzheimer’s Disease Psychosis
por: Gomar, J. J., et al.
Publicado: (2022)

Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms
por: Smith, Ruben, et al.
Publicado: (2023)

An autoradiographic evaluation of AV-1451 Tau PET in dementia
por: Lowe, Val J., et al.
Publicado: (2016)

Increased Uptake of AV-1451 in a Subacute Infarction Lesion
por: Cho, Soo Hyun, et al.
Publicado: (2018)

Quantification of Tau Load Using [(18)F]AV1451 PET
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

An updated radiosynthesis of [(18)F]AV1451 for tau PET imaging
por: Mossine, Andrew V., et al.
Publicado: (2017)

The Role of 18F-Flortaucipir (AV-1451) in the Diagnosis of Neurodegenerative Disorders
por: Roy, Saswata, et al.
Publicado: (2021)

Head-to-head comparison of tau positron emission tomography tracers [(18)F]flortaucipir and [(18)F]RO948
por: Smith, Ruben, et al.
Publicado: (2019)

Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy
por: Surova, Yulia, et al.
Publicado: (2015)

Cerebral [(18) F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy
por: Dickstein, D L, et al.
Publicado: (2016)

(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
por: Tsai, Richard M., et al.
Publicado: (2019)

Imaging Aβ and tau in early stage Alzheimer’s disease with [(18)F]AV45 and [(18)F]AV1451
por: Firouzian, Azadeh, et al.
Publicado: (2018)

Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson’s Disease
por: Surova, Yulia, et al.
Publicado: (2016)

Alteration of putaminal fractional anisotropy in Parkinson’s disease: a longitudinal diffusion kurtosis imaging study
por: Surova, Yulia, et al.
Publicado: (2018)

[(18)F]AV‐1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation
por: Bevan Jones, W. Richard, et al.
Publicado: (2016)

AV‐1451 tau and β‐amyloid positron emission tomography imaging in dementia with Lewy bodies
por: Kantarci, Kejal, et al.
Publicado: (2016)

Considerations and code for partial volume correcting [(18)F]-AV-1451 tau PET data
por: Baker, Suzanne L., et al.
Publicado: (2017)

(18)F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy
por: Passamonti, Luca, et al.
Publicado: (2017)

(18)F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy
por: Nicastro, Nicolas, et al.
Publicado: (2019)

(18)F‐AV‐1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy
por: Nedelska, Zuzana, et al.
Publicado: (2019)

[(18)F]-AV-1451 binding profile in chronic traumatic encephalopathy: a postmortem case series
por: Marquié, Marta, et al.
Publicado: (2019)

[(18)F]-AV-1451 binding in the substantia nigra as a marker of neuromelanin in Lewy body diseases
por: Mak, Elijah, et al.
Publicado: (2021)

Brain network alterations in individuals with and without mild cognitive impairment: parallel independent component analysis of AV1451 and AV45 positron emission tomography
por: Li, Yuan, et al.
Publicado: (2019)

[(18)F]AV‐1451 binding is increased in frontotemporal dementia due to C9orf72 expansion
por: Bevan‐Jones, Richard W., et al.
Publicado: (2018)

Imaging tau burden in dementia with Lewy bodies using [(18)F]-AV1451 positron emission tomography
por: Mak, Elijah, et al.
Publicado: (2021)

Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer’s Tauopathy
por: Murugan, N. Arul, et al.
Publicado: (2021)

Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism
por: Sjöström, Henrik, et al.
Publicado: (2019)

Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson’s case
por: Marquié, Marta, et al.
Publicado: (2017)

Binding of [(18)F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients
por: Schaeverbeke, Jolien, et al.
Publicado: (2019)

24S-Hydroxycholesterol Correlates With Tau and Is Increased in Cerebrospinal Fluid in Parkinson's Disease and Corticobasal Syndrome
por: Björkhem, Ingemar, et al.
Publicado: (2018)

MAPT rs242557 variant is associated with hippocampus tau uptake on (18)F-AV-1451 PET in non-demented elders
por: Shen, Xue-Ning, et al.
Publicado: (2019)

Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [(18)F]-AV-1451 PET data
por: Young, Christina B., et al.
Publicado: (2021)

Molecular pathology and synaptic loss in primary tauopathies: an (18)F-AV-1451 and (11)C-UCB-J PET study
por: Holland, Negin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h0urju1rrpi9uur3j3jvdci6ii